Search clinical trials for: Salmeterol/Fluticasone Capsair®

Total 336 results

Neutec Ar-Ge San ve Tic A.Ş

Terminated

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (COPD)

COPD

Turkey
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Henan University of Traditional Chinese Medicine

Unknown

A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients

Pulmonary Disease, Chronic Obstructive

China
University of Dundee

Completed

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma (CLE001)

Asthma

United Kingdom
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
Neovii Biotech
Fresenius Biotech North America

Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Ovarian Cancer

United States
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) (BADGER)

Asthma

United States
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Asthma

China
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Johns Hopkins University
GlaxoSmithKline; American Lung Association

Completed

Long-acting Beta Agonist Step Down Study (LASST)

Asthma

United States
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
University of Miami
GlaxoSmithKline

Completed

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

Asthma
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
Nemours Children's Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial (MICT)

Asthma

United States
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
University of Rostock
GlaxoSmithKline

Completed

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

Chronic Obstructive Pulmonary Disease | Smoke-related Lung Diseases

Germany
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Asthma

United States
Far Eastern Memorial Hospital
Research Ethics Review Committee

Unknown

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients

Quality of Life | Percentage of Annual Acute Exacerbation

Taiwan
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Far Eastern Memorial Hospital

Unknown

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Taiwan
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
GlaxoSmithKline

Completed

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Boehringer Ingelheim

Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Pulmonary Disease, Chronic Obstructive

Austria, Canada, France, Germany, Italy, Russian Federation, Sweden
GlaxoSmithKline

Completed

Viapaed Study In Children And Adolescents With Asthma

Asthma

Germany
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
GlaxoSmithKline

Completed

Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).

Asthma

Australia
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Asthma

Finland
GlaxoSmithKline

Completed

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Pulmonary Disease, Chronic Obstructive

United States
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Asthma

Finland
GlaxoSmithKline

Completed

Study Of Asthma In Patients Of African Descent

Asthma

United States
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
Mundipharma Korea Ltd

Terminated

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (RECONFFIRM)

Asthma
GlaxoSmithKline

Completed

Treatment Of Symptomatic Asthma In Children

Asthma

Netherlands
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
GlaxoSmithKline

Completed

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan

3

Subscribe